Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-1826 + adebrelimab + SHR-8068 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This combination drug consists of **SHR-1826**, **adebrelimab**, **SHR-8068**, and **bevacizumab**. It is being investigated for the treatment of advanced solid tumors, with a primary focus on **non-small cell lung cancer (NSCLC)**. SHR-1826 is a c-MET-directed antibody-drug conjugate (ADC) showing anti-tumor activity in MET-altered NSCLC; adebrelimab is a monoclonal antibody targeting PD-L1 (an immune checkpoint inhibitor); SHR-8068 is another investigational agent, likely immune-modulating; and bevacizumab is a well-established humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis and modulating tumor-induced immunosuppression. The mechanism of this combination is to simultaneously inhibit tumor growth, block pro-tumor angiogenesis, and enhance anti-tumor immune responses.
- Other names
- adebrelimab
02
Targets
VEGFA (Vascular endothelial growth factor A)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)MET (Mesenchymal-epithelial transition factor receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SHR-1826 + adebrelimab + SHR-8068 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-1826 + adebrelimab + SHR-8068 + bevacizumab.